Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$2.78 USD
+0.05 (1.83%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $2.78 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.78 USD
+0.05 (1.83%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $2.78 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Zacks News
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
by Zacks Equity Research
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arbutus (ABUS) stock based on the movements in the options market lately.
Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation (ABUS)
5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.
Arbutus Biopharma (ABUS) Jumps: Stock Rises 9.6%
by Zacks Equity Research
Arbutus Biopharma (ABUS) was a big mover last session, as the company saw its shares rise more than 9% on the day, amid huge volumes.
Alexion to Restructure Operations, to Lower Headcount by 20%
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that it will undertake a restructuring plan to re-align the global organization and cut workforce.
Alexion (ALXN) Licenses Artubus Technology for Rare Diseases
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) has recently licensed Arbutus Biopharma proprietary LNP technology for use in rare disease programs.
Celgene Issues Preliminary 2016 Results, Lifts 2017 View
by Zacks Equity Research
Celgene (CELG) announced preliminary 2016 results and upped guidance for 2017 at the J.P. Morgan Healthcare Conference.
Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
by Zacks Equity Research
Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.
Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
by Zacks Equity Research
Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
The Medicines Co LDL-Lowering Drug Positive in Phase II
by Zacks Equity Research
The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia.
Ultragenyx's (RARE) KRN23 Accepted for Review in the EU
by Zacks Equity Research
Ultragenyx (RARE) announced that EMA has accepted to review its MAA for KRN23 for the treatment of X-linked hypophosphatemia.
Bayer's sNDA for Stivarga Granted Priority Review in the U.S.
by Zacks Equity Research
Bayer (BAYRY) announced that the FDA has granted priority review designation to its sNDA for Stivarga for the second-line treatment of patients with uHCC.
Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data
by Zacks Equity Research
Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.
Innocoll (INNL) Down on FDA's Refusal to File Xaracoll NDA
by Zacks Equity Research
Innocoll (INNL) announced that it has received a Refusal to File letter from the FDA in connection with the NDA for Xaracoll for the treatment of postsurgical pain.
Fortress Biotech (FBIO) in Focus: Stock Moves 20.9% Higher
by Zacks Equity Research
Fortress Biotech, Inc. (FBIO) moved big last session, as its shares jumped almost 21% on the day.
Galena Biopharma Reveals Regulatory Pathway for GALE-401
by Zacks Equity Research
Galena (GALE) confirmed the regulatory pathway to advance GALE-401 (anagrelide CR) into a pivotal phase III study.
Intercept Pharmaceuticals (ICPT) Jumps: Stock Rises 9.3%
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) shares rose over 9% in the last trading session.
Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data
by Zacks Equity Research
Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.
NewLink Genetics (NLNK) Jumps: Stock Adds 10% in Session
by Zacks Equity Research
NewLink Genetics Corporation (NLNK) shares rose almost 10% in the last trading session.
Alexion Soliris Fails in Phase II/III Delayed Graft Function Study
by Zacks Equity Research
Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.
Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy
by Zacks Equity Research
Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.
Celgene (CELG) Otezla Approved in Japan for Two Indications
by Zacks Equity Research
Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.
Roche Presents Positive Follicular Lymphoma Data on Gazvya
by Zacks Equity Research
Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.
Pfizer Leukemia Drug Meets Primary Endpoint in Phase III
by Zacks Equity Research
Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint